172
G. Yang and Y. Huang
140. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V, Fossiez
F, Ryffel B, Schnyder B (2006) Interleukin-17 is a negative regulator of established allergic
asthma. J Exp Med 203(12):2715–2725
141. Chen L, Li DQ, Zhong J, Wu XL, Chen Q, Peng H, Liu SQ (2011) IL-17RA aptamer-mediated
repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis.
Osteoarthritis Cartilage 19(6):711–718
142. Reis J, Vender R, Torres T (2019) Bimekizumab: the first dual inhibitor of interleukin (IL)17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis. BioDrugs
33(4):391–399
143. Burmeister PE, Wang CH, Killough JR, Lewis SD, Horwitz LR, Ferguson A, Thompson
KM, Pendergrast PS, McCauley TG, Kurz M, Diener J, Cload ST, Wilson C, Keefe AD
(2006) 2 ‘-deoxy purine, 2 ‘-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics.
Oligonucleotides 16(4):337–351
144. Shahdadi Sardou H, Jebali A, Iman M (2020) Dual function of interleukin-23 Aptamer
to suppress brain inflammation via attachment to macrophage stimulating 1 kinase and
interleukin-23. Colloids Surf B Biointerfaces 185 (1873–4367 Electronic):110619
145. Lenn JD, Neil J, Donahue C, Demock K, Tibbetts CV, Cote-Sierra J, Smith SH, Rubenstein
D, Therrien JP, Pendergrast PS, Killough J, Brown MB, Williams AC (2018) RNA aptamer
delivery through intact human skin. J Invest Dermatol 138(2):282–290
146. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF (2007) The role of TNFalpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk.
J Lipid Res 48(4):751–762
147. Orava EW, Jarvik N, Shek YL, Sidhu SS, Gariepy J (2013) A short DNA aptamer that
recognizes TNFalpha and blocks its activity in vitro. ACS Chem Biol 8(1):170–178
148. Liu Y, Zhou Q, Revzin A (2013) An aptasensor for electrochemical detection of tumor necrosis
factor in human blood. Analyst 138(15):4321–4326
149. Mashayekhi K, Ganji A, Sankian M (2020) Designing a new dimerized anti human TNF-alpha
aptamer with blocking activity. Biotechnol Prog 28:e2969
150. Ge Y, Huang M, Yao YM (2018) Autophagy and proinflammatory cytokines: Interactions and
clinical implications. Cytokine Growth Factor Rev 43 (1879–0305 Electronic):38–46
151. Ramanathan M, Lantz M, MacGregor RD, Huey B, Tam S, Li Y, Garovoy MR, Hunt CA (1994)
Inhibition of interferon-gamma-induced major histocompatibility complex class I expression
by certain oligodeoxynucleotides. Transplantation 57(4):612–615
152. Legler DF, Thelen M (2016) Chemokines: chemistry biochemistry and biological function.
Chimia Aarau 70(12):856–859
153. Miller MC, Mayo KH (2017) Chemokines from a structural perspective. Int J Mol Sci
18(10):2088
154. Finsterer J (2004) Mitochondriopathies. Eur J Neurol 11(3):163–186
155. Roh YS, Seki E (2018) Chemokines and chemokine receptors in the development of NAFLD.
Adv Exp Med Biol 1061 (0065–2598 Print):45–53
156. Raghu H, Lepus CM, Wang Q, Wong HH, Lingampalli N, Oliviero F, Punzi L, Giori
NJ, Goodman SB, Chu CR, Sokolove JB, Robinson WH (2017) CCL2/CCR2, but not
CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in
osteoarthritis. Ann Rheum Dis 76(5):914–922
157. Gschwandtner M, Derler R, Midwood KS (2019) More than just attractive: how ccl2 influences
myeloid cell behavior beyond chemotaxis. Front Immunol 10:2759
158. Maasch C, Buchner K, Eulberg D, Vonhoff S, Klussmann S (2008) Physicochemical stability
of NOX-E36, a 40mer L-RNA (Spiegelmer) for therapeutic applications. Nucleic Acids Symp
Ser (Oxf) 52:61–62
159. Ninichuk V, Clauss S, Kulkarni O, Schmid H, Segerer S, Radomska E, Eulberg D, Buchner
K, Selve N, Klussmann S, Anders HJ (2008) Late onset of Ccl2 blockade with the Spiegelmer
mNOX-E36-3’PEG prevents glomerulosclerosis and improves glomerular filtration rate in
db/db mice. Am J Pathol 172(3):628–637
G. Yang and Y. Huang
140. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V, Fossiez
F, Ryffel B, Schnyder B (2006) Interleukin-17 is a negative regulator of established allergic
asthma. J Exp Med 203(12):2715–2725
141. Chen L, Li DQ, Zhong J, Wu XL, Chen Q, Peng H, Liu SQ (2011) IL-17RA aptamer-mediated
repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis.
Osteoarthritis Cartilage 19(6):711–718
142. Reis J, Vender R, Torres T (2019) Bimekizumab: the first dual inhibitor of interleukin (IL)17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis. BioDrugs
33(4):391–399
143. Burmeister PE, Wang CH, Killough JR, Lewis SD, Horwitz LR, Ferguson A, Thompson
KM, Pendergrast PS, McCauley TG, Kurz M, Diener J, Cload ST, Wilson C, Keefe AD
(2006) 2 ‘-deoxy purine, 2 ‘-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics.
Oligonucleotides 16(4):337–351
144. Shahdadi Sardou H, Jebali A, Iman M (2020) Dual function of interleukin-23 Aptamer
to suppress brain inflammation via attachment to macrophage stimulating 1 kinase and
interleukin-23. Colloids Surf B Biointerfaces 185 (1873–4367 Electronic):110619
145. Lenn JD, Neil J, Donahue C, Demock K, Tibbetts CV, Cote-Sierra J, Smith SH, Rubenstein
D, Therrien JP, Pendergrast PS, Killough J, Brown MB, Williams AC (2018) RNA aptamer
delivery through intact human skin. J Invest Dermatol 138(2):282–290
146. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF (2007) The role of TNFalpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk.
J Lipid Res 48(4):751–762
147. Orava EW, Jarvik N, Shek YL, Sidhu SS, Gariepy J (2013) A short DNA aptamer that
recognizes TNFalpha and blocks its activity in vitro. ACS Chem Biol 8(1):170–178
148. Liu Y, Zhou Q, Revzin A (2013) An aptasensor for electrochemical detection of tumor necrosis
factor in human blood. Analyst 138(15):4321–4326
149. Mashayekhi K, Ganji A, Sankian M (2020) Designing a new dimerized anti human TNF-alpha
aptamer with blocking activity. Biotechnol Prog 28:e2969
150. Ge Y, Huang M, Yao YM (2018) Autophagy and proinflammatory cytokines: Interactions and
clinical implications. Cytokine Growth Factor Rev 43 (1879–0305 Electronic):38–46
151. Ramanathan M, Lantz M, MacGregor RD, Huey B, Tam S, Li Y, Garovoy MR, Hunt CA (1994)
Inhibition of interferon-gamma-induced major histocompatibility complex class I expression
by certain oligodeoxynucleotides. Transplantation 57(4):612–615
152. Legler DF, Thelen M (2016) Chemokines: chemistry biochemistry and biological function.
Chimia Aarau 70(12):856–859
153. Miller MC, Mayo KH (2017) Chemokines from a structural perspective. Int J Mol Sci
18(10):2088
154. Finsterer J (2004) Mitochondriopathies. Eur J Neurol 11(3):163–186
155. Roh YS, Seki E (2018) Chemokines and chemokine receptors in the development of NAFLD.
Adv Exp Med Biol 1061 (0065–2598 Print):45–53
156. Raghu H, Lepus CM, Wang Q, Wong HH, Lingampalli N, Oliviero F, Punzi L, Giori
NJ, Goodman SB, Chu CR, Sokolove JB, Robinson WH (2017) CCL2/CCR2, but not
CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in
osteoarthritis. Ann Rheum Dis 76(5):914–922
157. Gschwandtner M, Derler R, Midwood KS (2019) More than just attractive: how ccl2 influences
myeloid cell behavior beyond chemotaxis. Front Immunol 10:2759
158. Maasch C, Buchner K, Eulberg D, Vonhoff S, Klussmann S (2008) Physicochemical stability
of NOX-E36, a 40mer L-RNA (Spiegelmer) for therapeutic applications. Nucleic Acids Symp
Ser (Oxf) 52:61–62
159. Ninichuk V, Clauss S, Kulkarni O, Schmid H, Segerer S, Radomska E, Eulberg D, Buchner
K, Selve N, Klussmann S, Anders HJ (2008) Late onset of Ccl2 blockade with the Spiegelmer
mNOX-E36-3’PEG prevents glomerulosclerosis and improves glomerular filtration rate in
db/db mice. Am J Pathol 172(3):628–637